Novel next-generation Bruton tyrosine kinase (BTK)-targeted protein degrader APG-3288 has received investigational new drug ...

Ascentage Pharma receives US FDA’s IND clearance for BTK degrader APG-3288 to treat patients with relapsed/refractory B-cell malignancies: Rockville, Maryland Friday, January 9, ...

Execute a pivotal program for potential best-in-class BTK degrader, bexobrutideg, including Phase 2 and confirmatory Phase 3 studies to support ...

Nurix Therapeutics (NRIX) stock: bexobrutideg’s BTK degradation shows strong efficacy in B-cell cancers, backed by $650M cash ...

In addition to orelabrutinib, we have fortified our powerful discovery engine to focus on cutting-edge targets for the development of autoimmune therapeutics through B-cell and T-cell pathways, with ...

Pirtobrutinib (Jaypirca®), a first-in-class noncovalent Bruton tyrosine kinase (BTK) inhibitor, has been approved by the FDA ...

Matching-adjusted indirect comparison (MAIC) of lisocabtagene maraleucel (liso-cel) versus axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) for treatment of third-line or later (3L+) ...